Mabwell(688062)2025-01-17 13:05Financial Performance - The company expects a net loss attributable to shareholders of the parent company for 2024 to be between -970 million and -1,160 million CNY, continuing the trend of losses compared to the previous year [2]. - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -1,000 million and -1,190 million CNY [2]. - The total profit for the previous year was -1,055.29 million CNY, with a net profit attributable to shareholders of the parent company at -1,053.43 million CNY [5]. - The company anticipates continued negative net profit attributable to shareholders of the parent company for the 2024 fiscal year [6]. Sales and Market Expansion - The company reported a significant increase in sales revenue due to market expansion, particularly from the drug Mai Li Shu®, which saw a substantial rise in sales compared to the previous year [6]. - The drug Mai Wei Jian® was approved for market launch in March 2024, contributing to increased sales revenue [6]. Operating Costs and R&D - Operating costs and sales expenses have increased in line with the expansion of commercialization efforts [6]. - The company maintains a high level of research and development investment, with multiple innovative drugs in critical trial stages [6]. Forecast Accuracy and Data Status - There are no significant uncertainties affecting the accuracy of this earnings forecast [7]. - The data provided is preliminary and subject to change, with final audited financial data to be disclosed in the 2024 annual report [8].